Sympathetic Blockade for Dysrhythmia Management in Heart Failure: Rationale and Therapeutic Progression to Intervention by Smith, Daryl I. & Duah, Albert O.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 2
Sympathetic Blockade for Dysrhythmia Management
in Heart Failure: Rationale and Therapeutic Progression
to Intervention
Daryl I. Smith and Albert O. Duah
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/66517
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Daryl I. Smith and Albert O. Duah
Additional information is available at the end of the chapter
Abstract
Continuous ganglionic blockade is being used increasingly to help manage ventricular 
tachydysrhythmias. The purpose of this chapter is to discuss the physiologic and ana-
tomic basis of ventricular tachydysrhythmias in detail that are mediated by the sympa-
thetic nervous system and to discuss appropriate indications for the use of sympathetic 
ganglion blocks. These blocks can be instituted as both destination and bridging thera-
peutic options to control these dysrhythmias. These blocks therefore have value in the 
heart failure patient population since they offer a means of controlling the dysrhythmias 
that can be devastating to an already compromised myocardium.
Keywords: electric storm, ventricular tachycardia, left cardiac sympathetic ganglion 
block, automatic implantable cardioverter-defibrillator, tachydysrhythmia
1. Introduction
1.1. Epidemiology of ventricular dysrhythmias in heart failure
Ventricular dysrhythmias present significant risk of death to patients suffering from heart 
failure resulting from valvular and ischemic diseases. Heart failure affects 6–10% of people 
over the age of 65 years [1]. Dysrhythmia in the setting of heart failure occurs at a reported 
incidence of 51% [2] and in studies it is reflected as causes of sudden death in patients diag-
nosed with congestive heart failure [3]. In otherwise healthy adults with frequent and complex 
ventricular ectopy, the long-term prognosis is similar to that of the healthy U.S. population 
and suggests no increased risk of death [4]. The implications are different in patients with 
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depressed left ventricular function after an acute myocardial infarction in this setting, high 
ectopy, greater than 10 PVCs per hour, is a useful risk marker of fatal or near-fatal arrhyth-
mias after myocardial infarction [5]. And in patients with CHF, nonsustained ventricular 
tachycardia (NSVT) is an independent marker for increased overall mortality rate and sudden 
death while the absence of NSVT and ventricular repetitive beats in a 24-h Holter indicates a 
low probability of sudden death [6].
It should be noted that VT and VF that occur in the setting of nonischemic dilated cardiomyopa-
thies, i.e., not associated with acute ischemic heart disease, are the most common result of reen-
try involving a region of myocardial scar. These ventricular scars that result in reentrant VT also 
occur in idiopathic dilated cardiomyopathies, hypertrophic cardiomyopathy, infiltrative heart 
disease (e.g., sarcoidosis), and right ventricular dysplasia. While ischemic VT/VF may resolve 
as the ischemic insult is corrected [7], the ectopic foci in nonischemic dilated cardiomyopathy 
are more incessant since they involve reentrant circuits that are created over time and more 
difficult to treat since the circuits are larger in the hypertrophic myocardium [8]. This is also a 
component of the vicious circle that is created as the ventricle either dilates or hypertrophies. 
In this setting, changes occur at the molecular level. These create a milieu more conducive to 
the development of reentrant circuits. In addition, the dysrhythmias themselves can also cause 
hypertrophic remodeling of ventricular myocardium and the cycle is further sustained [8].
1.2. Electrical storm
Electric storm is a variant of ventricular tachydysrhythmias (tachycardia or fibrillation) in 
which three or more sustained episodes of these dysrhythmias, or consequent shocks from an 
automatic implantable cardioverter-defibrillator occur within in a 24-h period. The syndrome 
typically manifests during acute myocardial infarction, in patients who have structural heart 
disease such as hypertrophic cardiomyopathy, in patients who have an implantable cardio-
verter-defibrillator, or in individuals suffering from an inherited dysrhythmic syndrome [9].
1.3. Description of strategies to control ventricular dysrhythmias
Efforts to control these dysrhythmias begin with pharmacologic interventions, progress to 
implantable devices to control or eradicate aberrant rhythms, followed by ablative techniques 
to locate and deactivate anatomic sites of dysrhythmogenesis, and frequently end in attempts 
to interrupt the sites of adrenergic innervation to the myocardium. The purpose of this chap-
ter is to review these techniques with emphasis upon the recent work on left sympathetic 
cardiac denervation.
2. Review of the neuroanatomy and physiology of sympathetic cardiac 
innervation
The optimal activity of the heart is regulated by the central nervous system through the 
autonomic innervation of the heart. Cardiac dysrhythmias and sudden cardiac death may 
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be a result of dysfunction of this cardiac activity-regulating circuitry [10]. Sympathetic and 
parasympathetic branches of the cardiac autonomic nervous system (ANS) work primarily 
through actions of cardiac pacemaker tissue to modulate heart rate and conduction velocity.
2.1. Sympathetic and parasympathetic innervation
Parasympathetic neurons receive preganglionic inputs from the vagus. The parasympathetic 
neurons synapse at ganglia located directly on the heart. These neurons have their cell bodies 
within the cardiac ganglia, arranged in discrete locations within the atrial epicardium, in plexi 
along the walls of the major cardiac vessels, and within the ventricular wall [11].
2.2. Neurotransmitters of the cardiac autonomic nervous system
The primary neurotransmitter in these cardiac parasympathetic ganglionic neurons is ace-
tylcholine; however, vasoactive intestinal polypeptide (VIP) and nitrous oxide may also be 
coreleased from parasympathetic terminals [12, 13]. The sympathetic neurons essentially use 
norepinephrine as their principal neurotransmitter, although other neurotransmitters, such 
as neuropeptide Y (NPY) and galanin, are coreleased from sympathetic terminals [14, 15]. 
Among other functions, NPY and galanin decrease acetylcholine release from adjacent para-
sympathetic terminals.
2.3. Anatomy of the cardiac autonomic nervous system
The preganglionic sympathetic fibers are located in the lateral column of the spinal cord travel 
along nerves and the adventitia of blood vessels to form three cervical ganglia and the first 
three or four thoracic ganglia [16]. Sympathetic cardiac neurons have their cell bodies within 
the three cervical ganglia, the superior cervical ganglion, the middle cervical ganglion, and 
the inferior cervical ganglion. The cardiac branches of the superior cervical ganglion (located 
in front of the C2 and C3 vertebrae) originate in the inferior sector of the ganglion and travel 
down the carotid and in front of the large muscles of the neck. The middle cervical ganglion 
located at the level of C6 and near the inferior thyroid artery has a cardiac branch that arises 
independently or appears after synapse with the inferior cervical ganglion. On the right side, 
it constitutes the dorsal part of the cardiac plexus and on the left side it converges at the 
deep part of the cardiac plexus. The inferior cervical ganglion is located between the base of 
the transverse process of the last cervical vertebra and the first rib, on the medial side of the 
costocervical artery. The cardiac branch of the inferior cervical ganglion converges with the 
recurrent nerve and with a branch of the medium cervical nerve before joining the deep part 
of the cardiac plexus [16]. This combination of inferior and middle cervical ganglion neu-
rons constitutes the paravertebral stellate ganglion. Ninety-two percent of retrograde-labeled 
nerves from the heart have their origins in the thoracic paravertebral ganglia [17, 18]. Thus, 
postganglionic cardiac sympathetic neurons have their cell bodies primarily in these ganglia.
Sympathetic efferent nerves are also present in the myocytes of the atrial and ventricular muscle 
and can thereby influence force of contraction and relaxation. For control of heart rate, the phys-
ical proximity of postganglionic cardiac parasympathetic and sympathetic axons to pacemaker 
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regions permits the formation of synapses and modulation of pacemaker function, through 
either acetylcholine inhibition of norepinephrine release or vice versa [11]. Parasympathetic 
effects on the sinus node predominate over sympathetic effects despite mutual modulation. 
The intrinsic cardiac nervous system provides an additional level of complexity within periph-
eral autonomic interactions. Within cardiac ganglia, integration of parasympathetic, sensory, 
and sympathetic inputs by way of local circuit neurons occurs. This level of integration is criti-
cal for local regulation of heart rate on a beat-to-beat basis via rapid temporal reflexes [11].
2.4. Theories of ventricular dysrhythmia generation
Aside from intraganglionic cross talk, interganglionic connections and descending inputs 
play a pivotal role in this regulation of heart rate on a beat-to-beat basis [19, 20]. Neuronal 
connections between sympathetic nerves and parasympathetic neurons also mediate prejunc-
tional autonomic interactions within the cardiac ganglia [21]. For example, ablation of the 
right atrial ganglion plexus attenuates vagal bradycardia while retaining vagal inhibition of 
sympathetic function [21, 22]. Armour et al. demonstrated neurons within the ganglia that do 
not project their axons beyond the ganglion (local circuit neurons) constitute a majority of the 
neurons in the mammalian cardiac ganglion [21, 23]. Cardiac ganglia therefore represent an 
important site for peripheral autonomic interactions.
The concept of sympathetic over activity, usually accompanied by reduced parasympathetic 
activity and heart rate variability, is increasingly recognized as a feature in the pathogen-
esis of a number of cardiovascular diseases [11]. Chen et al. postulated the nerve-sprouting 
hypothesis of sudden cardiac death which links nerve sprouting and electrical remodeling 
[24]. A number of studies have demonstrated the presence of aberrant sympathetic or para-
sympathetic outgrowth in human and canine hearts with atrial fibrillation [11]. Studies have 
demonstrated that ectopic or reentrant activity occurs at locations where autonomic fibers 
aggregate, such as the ligament of Marshall [11]. This has made ablation therapy, or localized 
cardiac denervation or block, a common option for reversing atrial or ventricular fibrillation 
episodes [11]. Foci for ventricular arrhythmia generation are much more likely to develop 
in areas where electrical signaling is discontinuous, such as an area of fibrosis, or where the 
myocardium is hypersensitive to catecholamines due to functional or pathological dener-
vation. Consequently, the effectiveness of these therapies has been affected by the residual 
presence of scar tissue or fibrosis that will continue to serve as a substrate for arrhythmia 
generation. It has been demonstrated that robust and prolonged sympathetic hyperinnerva-
tion also occurs in cardiac-projecting stellate ganglia after acute myocardial infarction [11].
3. Pharmacologic management of ventricular dysrhythmias
3.1. Classes of cardiac drugs and mechanisms of action
Pharmacologic management is the initial treatment option for ventricular tachyarrhythmias. 
Given that heart failure is a state with high catecholamine levels, drugs that act through the 
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decrease of this effect are of significant benefit [25]. The antisympathetic effect of beta block-
ers, for example, has been shown to be protective especially during myocardial ischemia 
by increasing the threshold for ventricular fibrillation and by reducing the catecholamine-
induced influx of calcium into cells during the repolarization phase of the cardiac action 
potential [26–28]. These protective effects are not absolute and may be lost with increase in 
sympathetic activity that cannot be compensated [29, 30]. A brief summary of the classes of 
cardiac drugs and their suspected mechanisms of action are shown in Tables 1 and 2.
We should elaborate here some of the current considerations of increased mortality associated 
with amiodarone therapy. This increased mortality with amiodarone exists in the setting of 
acute myocardial infarction and heart failure. Thomas et al. examined mortality related to 
amiodarone therapy at consecutive periods following acute myocardial infarction with heart 
failure and/or left ventricular systolic dysfunction. The postacute MI time periods studied 
were days 1–16, 17–45, 46–198, and 199–1096. The authors found significant increases in mor-
tality in 3 of the 4 periods (days 1–16, 17–45, and 199–1096). The group concluded that the 
use of amiodarone was associated with excess early and late all-cause mortality as well as 
cardiac-related mortality [44].
In another study examining amiodarone-related mortality, Torp-Pedersen et al. examined 
155 of 1466 NYHA class II patients who received amiodarone at baseline and 209 of 1563 
NYHA class III or IV patients who received amiodarone at baseline. Sixty-six percent of all 
the patients who received amiodarone were followed for 4 years. The authors found that 38.7–
58.9% of patients receiving amiodarone in NYHA class II and class III–IV, respectively, died, 
versus 26.2–43.3% not receiving amiodarone (p < 0.001). They concluded that amiodarone was 
associated with an increased risk of death. This risk was independent of functional class [45].
Class Agent studied Effect on mortality in CHF
I Propafenone [31]
Flecainide [31]
Encainide [31]
Moricizine [32]
Increase in death rate noted [31, 32]
II Metoprolol [33]
Carvedilol [34]
Bisoprolol [35]
Mortality decreased [33–35]
III Amiodarone [6, 36–39]
Dofetilide [40]
No demonstrable improvement in survival [6, 36, 37]
Possibly mortality reduction in nonischemic 
cardiomyopathy [38]
No improvement in mortality [40]
IV Verapamil [41–43] Does not affect VT caused by reentry and catecholamine-
sensitivity [41, 43]
Not studied in patients with VT/VF and CHF
Table 1. Summary of drug class application and efficacy in the setting of ventricular tachycardia/fibrillation and heart 
failure.
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3.2. Molecular bases of class II (β-blockers) cardiac drugs
As noted above, congestive heart failure is a condition associated with elevated levels of 
serum catecholamines and with all of the well-described sequelae of an increase in sympa-
thetic agonism. The mechanism of these effects is well described and pertinent to the under-
standing of the specific interventions discussed in this chapter and warrants review in order 
to knowledgeably address the treatment plan for ventricular tachyarrhythmias in the setting 
of congestive heart failure. When activated, the sympathetic fibers release norepinephrine, 
which binds to the transmembrane, GCPR-class β-adrenergic receptors. The receptors gen-
erate membrane-associated adenylyl cyclases (AC) which increases the membrane levels of 
cyclic adenylyl monophosphate (cAMP). This is transported across the cell membrane where 
it activates a number of intracellular effectors [46]. These effectors include phosphodiesterase 
(PDE), cAMP-dependent guanine nucleotide exchange factors (Epacs), [47–49] and protein 
kinase A (PKA). All of these play a role in the pathophysiology of heart failure with PDE and 
the Epacs acting on a cellular and genetic level in the pathologic remodeling of the hypertro-
phic myocardium [50, 51]. All of these effectors are activated by the binding of agonists to 
the β-receptor and each are tethered to their downstream targets by the A-kinase anchoring 
protein (AKAP) making them available for phosphorylation and subsequent deactivation or 
offset [52, 53]. In the case of protein kinase A which is the third and channel-specific effector, 
we find that in its activated form the kinase phosphorylates L-type calcium channels. This 
activation causes increased calcium entry into the cells. The calcium ion channel has an equi-
librium that is above the resting potential which results in depolarization when this potential 
Phase of cardiac action potential affected
Class I (sodium channel blockers)
Ia (quinidine, procainamide)
Phase 0 Na+ channel blockers; (intermediate association/
dissociation)
Ib (lidocaine, phenytoin) Phase 0 Na+ channel blockers (fast association/
dissociation)
Ic (flecanide, propafenone) Phase 0 Na+ channel blockers (slow association/
dissociation)
Class II (beta blockers)
Propranolol, metoprolol
Phase 4 (propranolol also shows some class I action); 
Metoprolol is a selective beta1-adrenergic receptor 
blocker that decreases the automaticity of contractions
Class III (potassium channel blockers)
Amiodarone, sotalol
Phases 1, 2, 4 (sotalol is also a beta blocker; amiodarone 
has class I, II, III, and IV activity, and is currently the 
drug of choice for acute, hemodynamically unstable 
ventricular tachycardia that is refractory to other 
antiarrhythmic agents)
Class IV (calcium channel blockers)
Verapamil, diltiazem
Phase 2 Ca channel blockers
Class V
Adenosine, digoxin
Unknown mechanisms (direct nodal inhibition)
Table 2. Summary cardiac drug classes and the cardiac action potential phase affected.
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is restored. In myocytes, the L-channel effector interaction increases membrane Ca2+ currents 
and Ca2+ release from the sarcoplasmic reticulum (SR) during each action potential, resulting 
in increased force production. In addition, Ca2+ reuptake into the SR is enhanced, thereby 
accelerating relaxation. Together, the inotropic (contractile) and lusitropic (relaxation) effects 
of sympathetic stimulation result in increased stroke volume [54]. In the sino-atrial node, 
activation of β-adrenergic receptors increases the heart rate via effector binding at both L-type 
and T-type channels. In this setting, as in the myocytes, an increase in cellular calcium entry, 
a more rapid return to the above-threshold resting potential, and subsequent depolarization 
occur when this potential is restored [55].
It is important to note that the tethering of the kinase to the calcium channel also makes it 
susceptible to rapid offset once the β-adrenergic stimulation has been removed.
The effectiveness of pharmacologic interventions in the treatment of ventricular dysrhyth-
mias in the setting of heart failure is not absolute. In the event of treatment failure with the 
initial pharmacologic approach, more invasive techniques may be employed. Currently, the 
literature supports the combination of electrophysiologically guided antiarrhythmic therapy 
with implantable defibrillators to reduce the risk of sudden death in high-risk patients with 
coronary disease. However, in this setting, antiarrhythmic drugs alone are not recommended 
[56]. In the following section, we discuss implantable devices, the next level step in the treat-
ment of CHF-related dysrhythmia.
4. Implantable devices and management of ventricular dysrhythmias
4.1. Automatic implantable cardiodefibrillators (AICD) and cardiac resynchronization 
therapy (CRT)
In a 2010 study, Tang et al. found that in patients with NYHA class II or III CHF and LVEF 
of 35% or less (one of the objective criteria of heart failure), amiodarone had no favorable 
effect on survival, whereas single-lead, shock-only AICD therapy reduced overall mortality 
by 23%. The median LVEF in patients was 25%; 70% were in NYHA class II, and 30% were in 
class III CHF. The cause of CHF was ischemic in 52% and nonischemic in 48%. AICD therapy 
was associated with a decreased risk of death of 23% and an absolute decrease in mortality of 
7.2% at 5 years in the overall population. Results did not vary according to either ischemic or 
nonischemic causes of CHF, but they did vary according to the NYHA class [57].
AICD therapy can be used alone as the primary, preventive treatment of recurrent ventricular 
tachyarrhythmias in order to reduce the total mortality from sudden cardiac death.
In this chapter, we will discuss only the indications for use of ICD in patients with nonisch-
emic heart failure (symptomatic with LVEF ≤ 35) as per guidelines set forth by the American 
College of Cardiology, the American College of Cardiology Foundation, the American Heart 
Association, the Heart Rhythm Society, and the New York Heart Association [58–62]. In this 
clinical setting, we find some variation in the specific aspects of recommendations for the 
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use of ICD. It is important to note the points of intersection of these recommendations with 
respect to the use of ICD in heart failure. All guidelines recommend ICD placement when 
nonischemic cardiomyopathy and heart failure coexist. Heart failure is defined objectively in 
the guidelines as a left ventricular ejection fraction (LVEF) less than 40% and in most of the 
studies less than 35%. The dysrhythmias for which the ICD is recommended in the heart fail-
ure setting are ventricular fibrillation, hemodynamically unstable ventricular tachycardias, 
ventricular tachycardia with syncope, and sustained ventricular tachycardia. Most of the 
guidelines indicate that ICD treatment should be used in conjunction with optimized medical 
therapy, and in patients who have a reasonable expectation of meaningful survival for more 
than 1 year (Table 3) [59].
Cardiac resynchronization therapy (CRT) is an alternate, more advanced form of device ther-
apy which is indicated for patients with systolic heart failure with quick response service 
(QRS) duration above 120 ms. The prolonged QRS is often associated with atrioventricular 
conduction delay and has been described as a risk factor for both all-cause cardiac death as 
well as sudden cardiac death (SCD) in patients with dilated cardiomyopathy [63]. CRT results 
in significant improvement in patients who have moderate-to-severe heart failure (NYHA 
class III/IV).
CRT allows biventricular pacing and was first described for use in congestive heart failure in 
1994 [64]. In addition to improving cardiac output by stabilizing contraction and ejection pat-
terns, it also has been shown to reverse pathologic remodeling of the hypertrophic ventricles 
in patients with congestive heart failure. This improvement is based upon the restoration 
of electrical synchrony with CRT which improves global cardiac function, energetics, and 
molecular and cellular phenotype [65].
The procedure for establishing a CRT pacing is more complex than that required to place 
an AICD alone. The technique involves insertion of a right ventricular endocardial lead via 
cephalic or subclavian vein approach as accomplished in AICD implantation. CRT also uti-
lizes the insertion of a left ventricular lead which is also placed with access to the left ven-
tricle obtained through cephalic or subclavian vein approaches. The most commonly used 
technique for left ventricular lead placement is to access the chamber via a coronary sinus 
tributary to reach the left ventricular free wall [66–68]. Khan et al. reported that the targeted 
approach to LV lead placement in CRT results in reversal of pathologic LV remodeling, clini-
cal status, and the improvement of patient outcomes at long term follow-up as determined by 
the endpoints of combined death and heart failure-related hospital admissions [68].
There exists a modification of CRT in which a defibrillator function is added (CRT-D) and a 
number of studies have compared the two modalities. A systematic review of the literature 
compared CRT and CRT-D revealed a decrease in all-cause death rate after 1 year with CRT-
D. These differences were noted in all-cause death rate after 1 year and cardiac death in the 
patients with LV impairment. The authors indicated that larger, randomized studies needed 
to be performed. In the review, subgroup analysis described four studies that addressed sud-
den cardiac death and revealed an odds ratio of 0.20 at the 95% confidence level in the lon-
gest follow-up period; and further subgroup analysis demonstrated superiority of the CRT-D 
group as an OR of 0.18 at the shorter follow period of >1 year [69].
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Clinical setting 
(myocardial 
derangement)
Left ventricular 
ejection fraction 
(LVEF)
Dysrhythmia Prior optimization of 
medical treatment
ICD therapy Expectation for 
survival
Type of prevention
CHF (by LVEF) [62] ≤40 VF or 
hemodynamically 
unstable VT; VT 
with syncope
N/A Recommended ≥1 year Secondary
Nonischemic dilated 
cardiomyopathy [62]
N/A but significant 
LV dysfunction
Sustained VT or VF Receiving chronic 
optimal medical 
therapy
Should be implanted ≥1 year N/A
Non-ischemic heart 
disease, NYHA class II 
or III [62]
≤30–35% N/A Receiving chronic 
optimal medical 
therapy
Recommended ≥1 year (with good 
functional status)
Primary
Nonischemic dilated 
cardiomyopathy, 
NYHA class II or III 
[58]
≤35% N/A N/A Indicated N/A N/A
Nonischemic dilated 
cardiomyopathy (or 
ischemic heart disease 
> 40 days post MI) [58]
≤35% N/A Receiving chronic, 
guideline-directed
Recommended ≥1 year (meaningful 
survival)
Primary
Table 3. Summary of the clinical recommendations of the use of ICD therapy in patients with nonischemic cardiomyopathy.
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In 2013, Gold et al. examined 419 patients from the REVERSE (Resynchronization reverses 
remodeling in systolic left ventricular dysfunction) trial, a multicenter, randomized trial of 
patients suffering from CHF who were randomized to active CRT, CRT-pacemaker, and CRT-
defibrillator groups. At 12 months of CRT, no significant difference in the study of primary 
outcomes was noted, however, at long-term follow-up which occurred over the ensuing 5 
years the group found improved survival in patients with heart failure [70].
In 2004, Bristow et al. compared CRT with and without an implantable defibrillator in 
advanced chronic heart failure. They evaluated 1520 patients of NYHA class III and IV heart 
failure due to ischemic and nonischemic cardiomyopathy. They examined a composite pri-
mary endpoint which consisted of time to death or hospitalization for any cause. The study 
revealed that CRT-P and CRT-D when compared to optimal medical therapy, each decreased 
the risk of the primary end point with hazard ratios of 0.81 (p = 0.014), and 0.80 (p = 0.01) 
respectively. The risk of the combined end point of death and time to hospitalization for heart 
failure was reduced by 34% in the pacemaker group (p < 0.002) and 40% in the pacemaker-
defibrillator group (p < 0.001) [71].
A decade later, Kutyifa et al. compared the effect of CRT-D with CRT-P in a high volume sin-
gle-center setting. In this study, 693 CRT-P devices and 429 CRT-D devices were implanted in 
patients with mean LVEF = 28.2 (±7.4%) and 27.6 (± 6.4%), respectively. The median follow-up 
period was 28 months. In the CRT-P group, 250 patients died compared with 129 patients in the 
CRT-D group for percentage mortalities of 36% and 30, respectively. This was not statistically sig-
nificant (p = 0.894). In patients with ischemic cardiomyopathy, CRT-D treatment was associated 
with a 30% risk reduction in all-cause mortality when compared with an implanted CRT-P (p = 
0.03). In nonischemic patients no benefit was seen in CRT-D over CRT-P (p = 0.15) [72]. Currently, 
there are no large scale studies that directly compare the efficacy or safety of CRT versus AICD.
It should be noted that in the setting of atrial fibrillation, a recent meta-analysis has sought 
to compare radiofrequency ablation versus antiarrhythmic drug therapy examining as pri-
mary outcomes of quality of life, morbidity, and mortality. The authors concluded from their 
data that RFA demonstrates an early but nonsustained superiority over antiarrhythmic drug 
therapy for the improvement of quality of life in patients with atrial fibrillation. Whether this 
can be extrapolated to ventricular tachyarrhythmias remains to be determined [73].
In an earlier single center study, Morillo et al. examined RFA versus antiarrhythmic drugs as a 
first line treatment of paroxysmal atrial fibrillation. These authors concluded that among patients 
with paroxysmal AF without previous antiarrhythmic drug treatment, ablation compared with 
antiarrhythmic drugs (AAD) resulted in a lower rate of recurrent atrial tachyarrhythmias at 2 
years. Recurrence was documented in approximately 50% of patients. Again, while the superi-
ority of RFA over AAD is asserted in this work, the extrapolation to the setting of ventricular 
tachyarrhythmias cannot be assumed until similar studies in this condition are conducted [74].
4.2. Ablation therapy
Unifocal ventricular ectopic beats (VEBs) are frequently seen in clinical practice and are usu-
ally benign in nature. In patients with heart disease, however, there is a risk of sudden car-
diac death from malignant ventricular arrhythmias if the VEBs persist and are frequent. As 
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discussed in the earlier section, β-blockers may be used for symptom control in patients with 
impaired systolic function and/or heart failure if there is a significant risk of sudden cardiac 
death from VEB-triggered tachyarrhythmias. In unifocal VEBs arising from the right ven-
tricular outflow tract in particular, catheter ablation may be considered in some patients as an 
adjunctive treatment [75].
In 1995, Zhu described the successful use of intracardiac mapping and radiofrequency cath-
eter ablation to eliminate drug-refractory monomorphic VEBs in severely symptomatic 
patients. They examined 10 patients who met the selection criteria of frequent monomorphic 
ventricular ectopic activity-related symptoms. These symptoms were frequent episodes of 
palpitation, fatigue, dyspnea, and light-headedness. The symptoms persisted for a mean of 
10 years (range 1–29). The criteria also included the inability to tolerate, or treatment failure 
with, at least three anti-arrhythmic drugs; no evidence of other cardiac arrhythmias (which 
differs from many other intervention criteria); and the absence of electrolyte abnormalities. 
All patients showed frequent ectopy with a mean of 17 (±11) VEB/min; or mean 1065 (±631) 
VEB/h with a range of 280–2094 VEB/h. The technique for ablation involved detailed map-
ping of the ventricular ectopic focus followed by definition of the earliest site of endocardial 
activation during spontaneous ventricular ectopic activity. Pace mapping was performed at 
the endocardial sites showing early activation (local endocardial potentials earlier than the 
surface QRS recording) during ventricular ectopic activity.
In their conclusion, the authors recommended the use of radiofrequency catheter ablation 
based upon the high success rate, the absence of complications, and resolution of symptoms 
related to frequent ventricular ectopic activity. The authors reemphasized that the ectopic 
activity target was monomorphic in nature and drug-resistant. The limitation of this work was 
the small sample size, the lack of true controls, and the inability to create true blinding, and fact 
that the data were collected from several centers without a standardized protocol. Based upon 
these data, with appropriate selection of patients, optimal clinical outcomes can be achieved.
The safety and efficacy of radiofrequency catheter ablation for ventricular tachycardia was 
evaluated by Calkins et al. in a prospective multicenter study. The work asserted that cath-
eter ablation of VT associated with structural heart disease is more difficult than ablation of 
idiopathic VT and reasoned that the larger size of responsible reentrant circuits in hyper-
trophic hearts made complete ablation a greater challenge. In their study, 146 patients with 
structural heart disease and ventricular tachycardia underwent an attempt at ablation. They 
were followed at 243 (±153) days. In 75% of the patients, all mappable VTs were eliminated. 
Fifty-seven patients (41%) had no VT of any type. Twelve patients (8%) experienced a major 
complication which the authors stated was a “moderate” incidence [8]. The major complica-
tions were four strokes or transient ischemic attacks, four episodes of pericardial tamponade; 
complete heart block in two patients; and myocardial infarction and aortic valve injury in one 
patient. The authors also describe four procedure-related deaths. Three of the four deaths 
occurred in patients with ischemic cardiomyopathy. In this group, one death was the result of 
a 99% occlusion of the left main coronary artery. This was caused by coronary artery emboli 
that ultimately lead to cardiogenic shock and death. In a second death, (also in a patient 
with severe ischemic cardiomyopathy), the initial insult was cardiac tamponade which was 
thought to be the result of the use of a transseptal approach to advance the ablation catheter 
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into the left ventricle. Following pericardiocentesis the patient developed pneumonia, pro-
gressive heart failure, and death 1 week later. A third death was attributed to a cerebrovascu-
lar accident that progressed to herniation and death. The fourth death was in a patient with 
ischemic cardiomyopathy with an LVEF = 15%, moderate mitral valve regurgitation and mild 
aortic insufficiency. The aortic insufficiency worsened after ablation and the patient under-
went a previously planned coronary artery bypass graft. An aortic valve replacement and a 
mitral valve annuloplasty were also performed. Surgical exposure revealed that the aortic 
valve was noted to be friable with a tear attributed to the ablation catheter. The patient suc-
cumbed to cardiogenic shock on the first postoperative day [8].
Long-term survival analyses in this study revealed 22 deaths that were not procedure-related. 
Of these, two deaths were attributed to noncardiac causes (cancer and chronic obstructive 
pulmonary disease). Sixteen were classified as cardiac nondysrythmic deaths (e.g., pump fail-
ure) and four deaths were thought to be secondary to ventricular dysrhythmia. The overall 1 
year survival postprocedure in the study was reported to be 75% [8].
The authors also report in this study that 54% of patients remained free of VT during follow-
up. It should be noted that in this study, Calkins et al. reported the postablation occurrence of 
any VT, which resulted in an ICD discharge as having a recurrence whether the VT was the 
monomorphic VT targeted by the ablation or whether it was a polymorphic VT that may have 
been thought unrelated. This was an admirable, effective, and purposeful attempt to remove 
possible bias [8].
There is considerably less data regarding catheter ablation in the setting of nonischemic car-
diomyopathy. Kottkamp et al. examined radio-frequency catheter ablation in eight patients 
with idiopathic dilated cardiomyopathy. The inclusion criteria for ablation were incessant VT 
(n = 4); frequent recurrent VT, reproducibly inducible with programmed electrical stimula-
tion (n = 5). Of the eight patients examined in this study, three had suffered “aborted sud-
den cardiac death” and two had experienced syncope [76]. Two patients were dependent on 
mechanical ventilation and were catecholamine dependent for circulatory support at the time 
of attempted ablation. Following the ablation, the authors report that six of the nine target 
VTs were rendered noninducible. In six patients, VTs with ECG morphologies other than 
the target VTs were inducible following RF catheter ablation. The authors concluded that 
RF catheter ablation in a select group of patients with idiopathic dilated cardiomyopathy is 
feasible with a higher success rate in patients with incessant VT and a moderate success rate 
in patients with chronic VT. It should be noted that in contrast to electrical storm (defined as 
multiple recurrences of ventricular arrhythmias over a short period of time) [77], incessant VT 
is defined as hemodynamically stable VT which persists for longer than 1 h [77].
5. Sympathetic denervation
5.1. History
The use of sympathetic denervation to treat disease is not new. The earliest reported observa-
tions of possible beneficial effects of resection of sympathetic nerves were written by Francois 
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Frank who examined the intervention in Graves’ disease (maladie de Basedow), epilepsy, 
glaucoma, and developmental delay. He also suggested in the work that angina might be 
treated by this resection as well [78]. In 1916, Jonescu used surgical left stellate ganglionec-
tomy to successfully treat a patient with incapacitating angina and cardiac dysrhythmias 
[79, 80].
The role of stellate ganglion interruption alone was brought into question by Danielopolu 
who stated that the maneuver would likely not control anginal events, and advocated more 
extensive denervation which would include C5 to T6 [81]. Interestingly, the advent and effi-
cacy of β-blockade therapy relegated sympathectomy to a less prominent role in management 
of heart disease [80]. The slow resurgence of sympathectomy came on the heels of a case report 
by Estes and Izlar in 2014 in which they described a patient with a refractory case of recur-
rent ventricular tachycardia. They performed bilateral cardiac sympathectomy and noted that 
after the operation there was normalization of a prolonged QRS conduction time [82]. In 1968, 
Zipes et al. presented a case of a patient with recurrent paroxysmal ventricular tachycardia/
fibrillation and reviewed three modes of therapy used to obtain complete suppression of the 
ectopic ventricular foci: pacing, cardiac sympathetic denervation, and β-adrenal blockade 
[83]. Subsequent animal research by Fowlis et al. emphasized work with acute myocardial 
ischemia in awake, canine models. In this study, bilateral cardiac sympathetic denervation 
was performed and the dogs underwent two-stage left coronary artery ligation 6 months fol-
lowing the sympathectomy. The group reported 22% mortality from ventricular fibrillation 
at 15 min in postsympathectomy animals compared to 52% in control animals. They noticed 
a similar trend at 24 h where they found 44% VF-related mortality and 65% VF-related mor-
tality in the postsympathectomy and control groups, respectively. The study also revealed a 
significantly greater percentage increase in the sinus cardiac rate 1 min after LCA occlusion 
in control animals versus postsympathectomy animals. Later onset ventricular dysrhythmias 
were noted as well as a lesser incidence of ventricular premature beats. They concluded that 
sympathectomy imparted a protective effect from VF following experimental coronary occlu-
sion in conscious animals [84].
5.2. Experimental foundation of sympathetic denervation
The experimental foundation for sympathetic denervation in treating ventricular tachyar-
rhythmias was further established in a study by Schwartz and Stone in 1980 in which they 
established the prevention of ventricular fibrillation by acute myocardial ischemia in a con-
scious canine model following sympathetic denervation [85]. In the human model, an ebb and 
flow existed in clinical confidence in left cardiac sympathetic blockade. This was caused by a 
perceived lack of reliable shortening of a prolonged QT interval in patients affected by syn-
dromes that involved this phenomenon and directly followed the landmark work of Moss and 
McDonald in 1971 [86]. The misconception was based upon the belief that a pharmacologic 
blockade of the left stellate ganglion would reliably recreate the physiologic effect of the tech-
nique used by Moss which resulted in Horner’s syndrome. Horner’s syndrome, which was 
classically used as a marker of an effective sympathetic blockade, does not ensure that the 
lower fibers of the stellate ganglion or the thoracic cardiac have been blocked. Currently, there 
remains a lack of rigorous clinical data. Treatment, then, is predicated upon extrapolation from 
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animal models and a growing number of clinical anecdotes and case series that are suggestive 
of the efficacy and safety of the technique in humans.
One of the few studies to critically examine the relationship between sympathetic hyper-
sensitivity as a clinical trigger of life-threatening dysrhythmias and the use of sympathetic 
denervation as a viable intervention was performed by Schwartz et al. [87]. In this placebo 
controlled, multicenter study, the efficacies of a β-blocker (oxprenolol), and selective, left car-
diac denervation were evaluated in patients with a first and anterior myocardial infarction. 
High (n = 144) and low (n = 869) risk groups were identified. The high-risk group consisted 
of patients who survived a myocardial infarction complicated by either ventricular fibrilla-
tion or ventricular tachycardia. The low-risk group consisted of 869 patients who suffered a 
myocardial infarction without dysrhythmia. The low-risk group was randomized to placebo 
or β-blockade with oxprenolol. The high-risk group was randomized to placebo, oxprenolol, 
or left cardiac sympathetic denervation. Crude death rates for each group were determined 
and both oxprenolol and left cardiac denervation reduced mortality to a level that was signifi-
cantly lower than observed in the placebo group (Table 4).
The authors concluded that left cardiac sympathetic denervation could be considered as an 
alternative for high-risk postinfarct patients for whom β-blockade is contraindicated.
Studies which followed this work were anecdotal in nature but tended to iterate this group’s 
findings. Despite lack of randomization and true controls, one study by Coleman et al. [88] 
examined videoscopic left cardiac sympathetic denervation for patients with recurrent ven-
tricular fibrillation/malignant ventricular fibrillation.
5.3. Sympathetic denervation in genetic channelopathies
The work of Coleman et al. is unique in that they studied the procedure in patients who did 
not carry the diagnosis of congenital long QT syndrome (LQTS). Their work was a single cen-
ter, retrospective examination of 91 patients who had videoscopic LCSD, with special atten-
tion to the 27 patients in the group who did have LQTS. The dysrythmogenic syndromes from 
which these patients did suffer included catecholaminergic polymorphic ventricular tachy-
cardia (CPVT) (n = 13); Jervell and Lange-Nielsen syndrome (n = 5) (congenital profound bilat-
eral sensorineural hearing loss and long QTC usually greater than 500 msec iron-deficiency 
Group Mortality rate (%) (n = 144) p-Value (difference from Placebo 
group)
Placebo 21.3 –
Oxprenolol 2.7 0.05*
Left cardiac sympathetic denervation 3.6 0.05*
*Statistical significance.
Table 4. Comparison of high risk, postinfarction group mortality rates in the clinical study of pharmacologic and surgical 
antiadrenergic interventions [87].
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anemia, and elevated levels of gastrin); idiopathic ventricular fibrillation (n = 4); left ventricu-
lar noncompaction (n = 2); hypertrophic cardiomyopathy (n = 1); ischemic cardiomyopathy 
(n = 1); and dysrythmogenic right ventricular cardiomyopathy (n = 1). Five patients had LCSD 
because of β-blockade intolerance. The authors concluded that LCSD may represent an antiar-
rhythmic intervention which is substrate independent for patients with life-threatening ven-
tricular dysrhythmias from causes other than long QT syndrome (Table 5) [88].
In a small study performed by Nademanee et al. in 2000, 49 patients who had electrical storm 
associated with a recent (mean 11 ± 10 days) myocardial infarction were divided into two 
groups in order to study the efficacy of “sympathetic blockade” versus antiarrhythmic agents 
as recommended by the Advanced Cardiac Life Support guidelines. It should be noted that in 
this study in the “sympathetic blockade” group, six of the 27 (22%) patients received stellate 
ganglion block, with seven (26%) receiving esmolol and 14 (52%) receiving propranolol. In 
the second, ACLS group patients received lidocaine (1 mg/kg IV bolus) followed by continu-
ous infusion of lidocaine (1–4 mg/min). Procainamide boluses of 100 mg were administered, 
if sinus rhythm was not obtained, up to a total dose of 500–1000 mg. This was followed by a 
continuous infusion of 2–4 mg/min. Procainamide was used in 16 patients (72%). Bretylium 
tosylate was given in 18 patients (82%) and administered in 5 mg/kg intravenous boluses and 
repeated every 5 min up to a maximum dose of 25 mg/kg if the VF recurred. All patients 
in the group received lidocaine and 12 patients (∼55%) received all three drugs at various 
points in the therapy. In the first week following the event 24 patients died. There were 18 
deaths in the ACLS group (82%) and six deaths in the sympathetic blockade group (22%). All 
deaths in the ACLS group were due to refractory VF. Among the six deaths in the sympathetic 
blockade group, three were from refractory VF, two were from electro mechanical dissocia-
tion and one was due to anoxic encephalopathy leading to asystole. The relative risk of dying 
in the ACLS group was 3.68 compared to the sympathetic blockade. At 1 year the reported 
survival rate for the ACLS group 2/22 (9%) as opposed to 20/29 (74%) for the sympathetic 
blockade group. This study, the authors admit, was limited by the fact that patients could 
Syndrome Total Post LCSD dysrhythmic event rate
Catecholaminergic polymorphic 
ventricular tachycardia
13 1/13
Lange-Nielsen syndrome 5 1/5
Idiopathic ventricular fibrillation 4 1/4
Left ventricular non-compaction 2 0/1
Hypertrophic cardiomyopathy 1 1/1
Ischemic cardiomyopathy 1 0/1
Arrythmogenic right ventricular 
cardiomyopathy
1 0/1
Table 5. Results of LCSD intervention in patients with life-threatening ventricular dysrhythmias from causes other than 
long Q-T syndrome are shown in this table.
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not be randomized to treatment arms because of the emergent nature of electrical storm. 
Therefore, the initial implementation in both groups of the accepted ACLS protocol occurred 
regardless of ultimate treatment direction. It should be noted, however, that both groups did 
demonstrate VF that persisted despite the ACLS and the authors correctly state that because 
of this there was no apparent predilection toward less refractory or more treatable VF in the 
sympathetic blockade. One significant omission in this study from our perspective is the lack 
of further survival analysis in the patients receiving left cardiac sympathetic denervation. 
These data could impact that rationale for use of LCSD as a standalone intervention. In their 
discussion, the authors reemphasize the role of increased sympathetic tone in patients with 
myocardial ischemia and cite animal as well as human studies showing that class I (sodium 
channel blocking) drugs such as lidocaine and procainamide can increase the risk of asystole 
and increase the QT interval, respectively [89, 90]. In addition, the authors assert and also 
correctly cite the fact that class I drugs exert negative inotropic effects and worsen cardiac 
function, leading to more heart failure, more episodes of ventricular fibrillation in patients 
who have left ventricular dysfunction, and mild congestive heart failure [91, 92]. The authors 
propose in conclusion that all patients with ES should be given β-blockers even if they suffer 
congestive heart failure, left ventricular dysfunction or dysrhythmias that cause hemody-
namic compromise.
6. Neural blockade and management of ventricular dysrhythmias
6.1. Technique of stellate ganglion blockade for management of ventricular dysrhythmias
Currently, the stellate ganglion block is typically performed using ultrasound guidance. In 
the not too distant past, before the advent of ultrasound-guided nerve blocks, the procedure 
was performed “blind,” i.e., using anatomic landmarks. While current practice still relies on 
anatomic landmarks to acquire the bearings for the block, ultrasound imaging is essential to 
obtain definitive confirmation that target structures have been visualized and accessed appro-
priately; and that structures that must be avoided (vascular, respiratory, esophageal, endo-
crine, etc.) are successfully identified. The linear ultrasound transducer provides the most 
manageable access to this region.
With the patient in the supine position the lateral neck and the base of the neck are sterilely 
prepped and draped. The carotid artery is digitally retracted laterally and the ultrasound 
transducer is positioned close to the longus colli muscle. The transducer is then gently pressed 
between the carotid artery and trachea at the level of the cricothyroid membrane. This cor-
responds to the level of the transverse process of the sixth cervical vertebra or Chassaignac’s 
tubercle (Figure 1).
An inplane approach (block needle and ultrasound transducer long axes in the same orienta-
tion) is used. If a continuous/catheter technique is to be used, an 18 gauge Tuohy is inserted 
paratracheally toward the middle of the longus colli muscle. The needle insertion endpoint is 
the ultrasound image demonstrating the tip of needle penetrating the prevertebral fascia in 
the longus colli (Figure 2).
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Figure 1. Placement of ultrasound transducer for ultrasound-guided left stellate ganglion block. Courtesy of the New 
York Society of Regional Anesthesiology (NYSORA).
Figure 2. Ultrasound of left stellate ganglion (indicated by long yellow arrows) and related anatomy are shown. Note 
proximity to the carotid artery (CA) and the internal jugular (IJ) vein. The short green arrows indicate the block needle. 
Courtesy of the New York Society of Regional Anesthesiology (NYSORA).
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Following attainment of the prevertebral fascia of the longus colli muscle, negative aspira-
tion for blood and cerebrospinal fluid must be demonstrated. Local anesthetic is injected 
and its spread is visualized in real time. Under sterile conditions, a 20 gauge polyethylene 
catheter is inserted through the Tuohy needle to the left stellate ganglion within the pre-
vertebral fascial layer. An intervascular approach between the left carotid artery and 
the left internal jugular vein may be used if dictated by anatomical restrictions (Figure 3). 
A continuous infusion of 1 mL per hour of 1% preservative free lidocaine may be initiated 
[93].
6.2. LCSD for ventricular dysrhythmias: review of case reports in the literature
In his thorough review of the evaluation and management of electrical storm, Effing et al. 
mentioned left stellate ganglion blockade as a means of suppressing electrical storms that 
were refracting to multiple antiarrhythmic agents and B-blockade. The review, however, does 
not mention the anecdotal reports of successful stellate ganglion blockade in VT/VF refractory 
which is refractory to countershock administered by AICD. At the time of this writing there 
are five case reports or case series in the recent literature, which address successful use of 
LCSD accomplished via somewhat different methods to treatment recurrent VT and electrical 
Figure 3. Ultrasound of left stellate ganglion (SG) block using the intervascular approach between carotid area (CA) 
and internal jugular (IJ) vein is shown. VA is vertebral artery; dashed red line is course of 18 gauge Tuohy needle and 
subsequent 20 gauge polyethylene catheter [93].
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storm. This section addresses each of these reports in chronologic order and compares the 
specific clinical settings in which they were used.
In 2009, Collura et al. performed an electronic medical record review of 20 patients at their 
institution who received LCSD for the treatment of two cardiac channelopathies: long QT 
syndrome and catecholaminergic polymorphic ventricular tachycardia (CPVT). Their study 
population consisted of 20 patients with an age range of 2 months to 42 years; with a gender 
component of 8 females and 12 males. Eighteen of the patients received the VATS proce-
dure and two had a traditional or “open” approach for the LCSD. They reported no intraop-
erative ectopy, no uncontrolled hemorrhage, and no VATS case requiring conversion to an 
open approach nor any other perioperative complication in their short term follow-up period 
(mean 16.6 ± 9.5 months). They found a “marked” reduction in cardiac events in patients (n = 
11) who received LCSD as secondary prevention [94].
Mahajan et al. 2005 took a different approach to accomplishing LCSD. In their case report, 
they describe thoracic epidural anesthesia (TEA) for electrical storm [95]. Their decision to 
attempt control with TEA was based on extrapolation from the work of Blomberg et al. who 
found significant symptomatic improvement in patients suffering from intractable angina, in 
addition to finding attenuation of stress induced myocardial ischemia [96]. Their attempt was 
also bolstered by the editorial remarks of Staats and Panchal [97] which supported the use of 
this technique in the coronary care unit for patients with severe angina [97]. In their report, 
Mahajan et al. describe a 75-year-old man with a history of ischemic cardiomyopathy (LVEF 
= 20%); an AICD (with 86 shocks and 42 antitachycardia pacing attempts over a 48-h period); 
and a history of two separate coronary artery bypass grafting procedures 15 years apart. The 
patient was being treated with maximal antiarrhythmic therapy (mexilitene, amiodarone, 
nitroglycerine, and esmolol) and deemed ineligible for further coronary revascularization. 
The patient’s AICD battery was depleted and general endotracheal anesthesia was required 
for radiofrequency ablation and the AICD battery change. The patient continued to have VF/
VT despite increasing doses of anesthetics and antidysrhythmics. The patient received an 
“emergent” thoracic epidural catheter placement in the hope of controlling the dysrhythmias 
and an infusion was begun. They report that during the time of the epidural infusion only one 
episode of VF occurred.
Loyalka et al. [98] discuss a 58-year-old male with a history of a complete Q-wave ante-
rior myocardial infarction who developed unstable ventricular dysrhythmias treated with 
repeated external countershocks. The patient’s condition then deteriorated to pulseless 
ventricular dysrhythmias which required a series of direct current shocks and amioda-
rone for stabilization. The patient underwent an urgent implantation of a percutaneous 
ventricular assist device (Tandem Heart) which accomplished left atrial-femoral artery 
bypass. The dysrhythmias were reported to have persisted at which point a left stellate 
ganglion block was performed with 0.25% bupivacaine. After the block the patent required 
a single defibrillation of 200 J and had no further sustained dysrhythmias. Following the 
procedure, they reported frequent premature ventricular contractions and short 3–5 beat 
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of nonsustained ventricular tachycardia. The patient developed an ectopic atrial tachycar-
dia which was mapped and ablated. He received a dual chamber AICD. The authors cor-
rectly note that this is currently the only case found in the literature of such a description 
to have been successfully treated with left atrial femoral support and left stellate ganglion 
block [98].
In 2014, Malik et al. reported the successful treatment of a 70-year-old man who suffered from 
ischemic cardiomyopathy and had an AICD. The patient had developed intractable VT which 
was resistant to amiodarone, lidocaine, and multiple unsuccessful radiofrequency catheter 
ablation attempts of the ectopic foci. The patient continued to have up to 18 AICD shock-
able events per day. At 2.5 h, following a stellate ganglion block the ventricular tachycardia 
reverted to a normal sinus rhythm which persisted for at least 1 month which is the latest 
reported follow-up in the case study [99].
Finally, in 2015 this author (Smith et al.) published a report of a 65-year-old male with a 
diagnosis of electric storm and a history of nonischemic cardiomyopathy, prostate cancer, 
and a previously placed left ventricular assist device. The patient received a continuous 
left stellate ganglion block which was continued for 7 days. Based upon the result of this 
block, a surgical (open technique) left cardiac sympathetic denervation was performed. It 
was important for us in this case to establish a continuous left sympathetic blockade infu-
sion for 6 days in order minimize the likelihood that we were simply observing a period 
of spontaneous ectopic quiescence [93]. No definitive studies have addressed specifically 
the optimal time for blockade before definitive treatment is employed. At our institution, 
we also used 1 week by convention to allow for reversal of the patients’ coumadin ther-
apy with bridging using a heparin infusion during this period. At the same time, in each 
of our cases, there was a marked reduction in the number of episodes of daily shockable 
events (DSEs). Statistical analysis of the number of individuals treated by this technique 
at our institution remains too small for rigorous statistical analysis. We did however look 
at the mean number of DSE both prior to and following each intervention over a 6 day 
week or a 144 h period considered as 144 sample times. In our observations, we found no 
noticeable difference in the number of DSE’s between the postblock and the postsurgical 
interventions. We found that differences between DSE preintervention and postblock did 
exist and examined these on an intrapatient basis. For differences between preinterven-
tion and postintervention, we used a repeat measures t-test and found a preinterven-
tion DSE value (5.5 ± 4.04) postblock DSE (0.38 ± 4.04). We looked at the two patients in 
whom we proceeded to permanent blockade and found intrapatient differences in DSE 
value. We used the same mean overall DSE in the eight total patients and defined that 
as our “population” (5.5 ± 4.04). This was done despite the fact that the mean DSE in 
the two patients who preceded to permanent denervation techniques was higher than 
in the “population.” Our intention here was to more critically compare the differences 
pre and postintervention and to reduce bias as well. We found intrapatient differences at 
the p ≤ 0.004 and p ≤ 0.0048 levels, respectively. Currently, we use these determinations 
applied to intrapatient results to direct our care on a case by case basis. Table 6 pres-
ents the summary of case studies in the literature which employed LCSD for ventricular 
tachydysrhythmias.
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Study, (year) Type of work N Population,(patient) Clinical setting Technique Outcome Comment
Mahajan et al. [95] Case report 1 75-year-old man ES, LVEF; 
antidysrhythmic 
therapy failure
Thoracic epidural Cessation of 
sustained VT
Proceeded 
to get VAD 
(left atrial—
femoral 
bypass)
Collura et al. [94] Retrospective 
electronic chart 
analysis
20 2-months old to 
42-years old (8 female, 
20 male)
LQTS and CPVT Surgical 
ganglionectomy; 18 
VATS and two open
No perioperative 
ectopy; no 
hemorrhage; no 
VATS – open 
conversion 
determined safety 
of procedure*
Marked 
reduction 
in cardiac 
events in post 
getting LCSD 
as secondary 
prevention
Loyalka et al. [98] Case report 1 58-year-old man Anterior MI; 
unstable VT; 
repeated external 
countershocks; 
amiodarone
Stellate ganglion 
block (single)
1 Post-procedure 
defibrillation. No 
further events.
Ablation of 
developed 
ectopic atrial 
tachycardic 
focus; AICD 
placement
Malik et al. [99] Case report 1 70-year-old man Ischemic 
cardiomyopathy, 
AICD, intractable 
VT; failed RF 
ablation; ES
Stellate ganglion 
block (single)
VT reverted to NSR 
2.5 h after block. 
Lasted through one 
month follow-up 
period
Smith et al. [93] Case report 1 65-year-old-man ES, AICD, LVAD Continuous stellate 
ganglion block
Open surgical 
ganglionectomy 
performed at day 7 
of continuous block 
based on results
Table 6. Summary of the case study literature on stellate ganglion blockade for ventricular tachydysrhythmia.
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7. Anticoagulation considerations for neural blockade for management of 
ventricular dysrhythmias
The incidence of hemorrhagic complications associated with neuraxial blockade is not known 
but has been cited as 1 in 150,000 epidurals and 1 in 220,000 spinals in the literature. Recent 
epidemiologic data suggest that in certain populations, the incidence may be higher. Because 
of the proximity of the stellate ganglion to the neuraxis and the potentially catastrophic con-
sequences of intracervical hemorrhage, we treat this block as if were a neuraxial block and 
apply the same precautions used in actual neuraxial injections [100]. Underlying abnormali-
ties of the spinal cord, preexisting coagulopathy, increasing age, difficulty placing needle, and 
indwelling neuraxial catheter in the setting of sustained anticoagulation are risk factors for 
clinically significant bleeding associated with neuraxial and certain regional blockade tech-
niques [101]. These present challenges for clinicians performing regional anesthesia in such 
patients. Due to the safety concerns of bleeding risk, several agencies including American 
Society of Regional Anesthesia (ASRA), American College of Chest Physicians (ACCP), and 
European Society of Regional Anesthesia (ESRA) have provided guidelines and recommenda-
tions to reduce patient morbidity/mortality during regional anesthesia. For patients taking 
anticoagulants, these guidelines and recommendations for practicing regional anesthesia are 
based on available evidence from epidemiologic data with the goals of making hospital-based 
medical practice standard, optimizing patient outcomes, and ensuring quality patient care 
[102]. Variation from these recommendations may be acceptable since no specific clinical out-
come can be guaranteed from the suggested guidelines. Patient factors as mentioned earlier, 
clinician expertise and choice of materials/medications can influence clinical outcome and 
experience.
There are no current laboratory models and cervical hematomas are rare which makes con-
structing prospective-randomized studies a challenge. These practice guidelines or recom-
mendations are therefore a summary of evidence-based reviews and the collective experience 
of recognized experts in regional anesthesia and anticoagulation [102]. To this end, the 
decision to perform stellate ganglion blockade (either via single injection or via continuous 
infusion catheter), and the timing of catheter removal in a patient receiving antithrombotic 
therapy should be made on an individual basis, taking into account the risk of cervical hema-
toma with the benefits of regional anesthesia for a specific patient. Published guidelines and 
recommendations should be used to mitigate confusion.
Understanding pharmacokinetics and pharmacodynamics of anticoagulation therapy, tim-
ing of administration and determining the appropriate time to conduct a safe procedure is 
essential to performing regional anesthesia in an anticoagulated patient [103]. Alternative 
anesthetic and analgesic techniques should be considered in patients with an unacceptable 
risk. However, some of these recommendations should be applied when performing regional 
anesthesia in every patient on anticoagulation. Coagulation status should be optimized at the 
time of sympathetic neural needle/catheter placement, and the level of anticoagulation must 
be carefully monitored during the period of perineural catheterization [102]. Indwelling cath-
eters should not be removed in the setting of therapeutic anticoagulation as removal seems 
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to significantly increase the risk of hematoma. Identification of risk factors and establishment 
of guidelines will not completely eliminate complication of regional anesthesia in an antico-
agulated patient. Vigilance in monitoring is critical to allow early evaluation of neurologic 
dysfunction and prompt intervention. Protocols must be in place for urgent magnetic reso-
nance imaging and hematoma evacuation if there is a change in neurologic status. We must 
focus not only on the prevention of intracervical or perineural hematoma but also on rapid 
diagnosis and treatment to optimize patient outcome.
8. Ventricular dysrhythmias and AICD-discharge-related anxiety 
syndromes
In some patients, the persistence of ventricular dysrhythmias and subsequent AICD dis-
charges can have distressing effects. This becomes a vicious cycle in which the shock itself 
and anticipation of the pain and discomfort associated with the shock can cause significant 
anxiety, increase the level of hormones associated with stress, and thus, potentially increase 
the incidence of adrenergic-susceptible ventricle tachyarrhythmias. The data on this phenom-
enon are not absolutely consistent. At least one study reports the absence of impact on emo-
tional distress. In 2003, Ladwig et al. described 37 patients with chronic atrial fibrillation, 
mean age 61.9 with a gender breakdown of 29 men and 8 women. They assessed pain percep-
tions of low energy test shocks (60 V, O.1 J) immediately following the discharge. The group 
also collected data from the patients regarding treatment anxiety, depression, and somatiza-
tion. Forty one percent of patients (n = 15) perceived the shocks as hypalgesic, 10 patients 
(27%) perceived it as normalgesic and 12 patients (32%) perceived it as hyperalgesic. They 
also noted that the pain threshold was significantly lower (p ≤ 0.029) in patients in which AF 
was accidentally diagnosed and an inappropriate discharge was delivered. They state that 
the hyperalgesic pain threshold was not associated with anxiety depression, or the patient’s 
tendency to amplify benign bodily sensations [104]. It should be noted that while this study 
aims to examine the impact of countershocks on patient emotional status, and pain percep-
tion, it may be nonrepresentative in at least two ways. First, the dysrhythmias examined are 
atrial and it is unclear whether the patient experience can be extrapolated to the ventricular 
dysrhythmia setting. Second, the experimental protocol in this work used a low-energy test 
shock of 60 V, 0.1 J. The mean energy delivered for ventricular defibrillation is reported to be 
10 J, with maximum shock energies ranging between 25 and 42 J with many monomorphic 
tachycardias terminable with shocks of 1 J or less [105]. The authors also state that low-energy 
cardioversion should always be backed up by successive high-energy shocks, since ventricu-
lar dysrhythmias can accelerate after low-energy shocks [106]. Thus, even when low-energy 
cardioversion is used in the ventricular dysrhythmia setting it is frequently still 10-fold greater 
than that reported in the Ledwig study on atrial dysrhythmias.
The remainders of the studies that examine psychological effects of AICD discharge do report 
some negative impact on emotional well-being and quality of life (QoL). These studies empha-
size various aspects of life that are worth mentioning since the control of the total number of 
AICD discharges as well as the effective management of electrical storm is the goal of LCSD.
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The advent of advanced cardiac support interventions will undoubtedly lead to more patients 
surviving recurrent VT. In this regard, LCSD should be considered more frequently since the 
number of patients living with this diagnosis will increase and lead to an overall increase in 
the number of individuals suffering a decrease in QoL. These patients will likely enter the 
palliative care setting. We will look at some of these studies chronologically with the ultimate 
goal of understanding how LCSD may possibly impact those Q0L components.
One of the earliest descriptions of the psychiatric syndromes identified in patients with AICD 
was given by Fricchione et al. in 1989 and included anxiety, psychological dependence, abuse, 
and withdrawal [107]. Later Hamner and his group examined three cases involving patients 
with AICD. He reported that all the patients met the criteria for PTSD based on DSM-IV crite-
ria, i.e., stressor, intrusive recollection, avoidance/numbing, hyper-arousal, duration (greater 
than one month), and functional significance (causes impairment in important areas of func-
tioning [108]. In the first patient, Hammer describes the resolution of the PTSD, came in the 
form of the addition of fluoxetine to his established regimen which included amitriptyline 
and lorazepam. This was followed by cardiac transplantation and subsequent removal of his 
AICD. The remaining two patients in the case study were treated with either a dual reup-
take inhibitor of serotonin and norepinephrine (duloxetine), or a selective serotonin reuptake 
inhibitor (paroxetine) antidepressant, and psychotherapy in combination with preestablished 
anxiolytics and tricyclic antidepressants. The group emphasized the important potential for 
the development of PTSD secondary to AICDs. They correctly state that the effectiveness of 
psychotherapy and/or psychopharmacology in treating AICD related PTSD has not been sys-
tematically investigated [108].
In a 1999 literature review, Sears et al. concluded that 13–38% of AICD recipients experienced 
diagnosable levels of anxiety with rates of clinical depression that were comparable to other 
cardiac patient populations. They reported AICD-related concerns, e.g., fear of shock, fear of 
device malfunction, fear of death, and fear of embarrassment. They concluded that young 
recipients and those with high discharge rates may experience the most adjustment difficul-
ties [109].
Two papers published in 2002 turned focus onto QoL issues by distinct definition. In that year, 
Sears et al. [110] compared QoL studies that examined antidysrhythmic therapy with AICD. 
They noted that the primary focus of these studies was upon mortality rather than AICD-specific 
and antiarrhythmic-specific measures that may be more sensitive to psychological outcomes. 
They stated that the existing work suggested that the ICD achieved comparable if not better 
QoL than alternative treatments, but stated that future measurements and interventions should 
focus on patient acceptance of the device. The group also recommended that routine integration 
of psychosocial needs considerations should be added to the clinical care of patients with AICD. 
Also, in 2002, Schron et al. provided three self-administered instruments to measure generic 
and disease specific QoL in the antiarrhthmics versus implantable defibrillators (AVIDs) trial 
participants. They reported that overall AICD and antiarrhythmic drugs (AAD) were associated 
with similar alterations in QoL with the development of sporadic shocks and adverse symptoms 
associated with reduced physical functioning and mental well-being and increased concerns 
The Role of the Clinical Cardiac Electrophysiologist in the Management of Congestive Heart Failure44
among ICD recipients; and reduced physical functioning and increased concerns among AAD 
recipients [111].
In another study that focused on the psycho social impact of AICD on spouses, Sowell 
et al. in 2007 examined patients and their spouses (n = 62) who completed separate indi-
vidual assessment batteries regarding demographics, death anxiety, shock anxiety, general 
anxiety, and marital adjustment at a single time point during outpatient cardiology visits. 
Their results revealed similar general anxiety and marital adjustment among participants 
with spouses actually reporting greater shock anxiety than did the patients themselves 
(p = 0.045). The study also revealed that female ICD patients reported more anxiety related 
to death and shock and received more shocks given identical degrees of clinical severity 
(p = 0.02) [112].
In what may the most definitive study to date, Mark et al. in a randomized trial compared 
AICD therapy or amiodarone with state of the art medical therapy alone, found that psy-
chological well-being in the AICD group, as compared with medical therapy alone was sig-
nificantly improved at 3 months (p = 0.01) at 12 months (p = 0.003); but not at 30 months. It 
should be emphasized that this study not only compared to AICD and medical therapy but 
also examined changes in scores on the medical outcomes study 36 item short form (SF-36) 
scale for patients who had received an ICD shock which they calculated as the difference 
between the most recent overall QoL category score that existed prior to the shock and that 
which the patient noted immediately following a shock. In each of the five categories (gen-
eral health perceptions, physical function, emotional function, social function, and self-rated 
health) there were statistically significant decrements in QoL [113].
9. Summary
The summary of the progression from diagnosis to treatment with LCSD described in this 
chapter is found below.
The use of neural blockade has thus far been applied as a last resort [88] in the treatment of 
malignant ventricular tachyarrhythmias in the setting of heart failure. This chapter has exam-
ined the progression of therapeutic intervention from least invasive (pharmacologic only) to 
the most invasive techniques and interventions. Whether or not this is the optimal organiza-
tional approach to these maladies is difficult to discern. Given the acuity and the potential 
severity of the ventricular tachyarrhythmias, it is extraordinarily difficult to construct true 
randomized, controlled trials in human subjects to specifically answer these questions and 
potentially optimize the progression from one treatment modality to the next. In the future, 
modifications in all aspects of care for these patients will no doubt be addressed particularly 
with regard to how specific neural blockade of the left cardiac sympathetic innervation can 
be implemented in a more timely and patient-convenient fashion with the goal of overall 
improvement in clinical outcomes of survival as well as in quality of life.
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